Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 6/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23235854 | 0.99 | PRSS1 (0.54) | PRSS1PRSS2PRSS3F2PARP10 | |
| SCHEMBL23901824 | 0.94 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F2PARP10 | |
| Hydrochloric Acid SCHEMBL23235874 | 0.93 | PRSS1 (0.52) | PRSS1PRSS2PRSS3F2PARP10 | |
| SCHEMBL23566027 | 0.89 | NISCH (0.56) | NISCH | |
| Hydrochloric Acid SCHEMBL23880700 | 0.88 | NISCH (0.55) | NISCH | |
| SCHEMBL23902266 | 0.84 | NISCH (0.53) | NISCH | |
| SCHEMBL23902206 | 0.84 | F10 (0.40) | PRSS1PRSS2PRSS3F2NISCH | |
| SCHEMBL23902298 | 0.83 | F2 (0.54) | PRSS1PRSS2PRSS3F2TMPRSS6 | |
| SCHEMBL23566464 | 0.82 | NISCH (0.58) | NISCH | |
| SCHEMBL23566019 | 0.81 | PRSS1 (0.84) | PRSS1PRSS2PRSS3F2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | PRSS1 652/4885PRSS2 1318/4885PRSS3 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.